Therapeutic drug monitoring of anti–tumor necrosis factor in patients with inflammatory bowel disease allows gastroenterologists to make more effective treatment decisions, a recent prospective study found.
Physicians who used TDM in their decision-making process were able to improve rates of clinical remission and reduce unnecessary treatment among their patients with IBD. The study, which was conducted by researchers from the Institute of Biomedical Investigation of Girona, Spain, was